DOM-MELOXICAM TABLET
국가: 캐나다
언어: 영어
출처: Health Canada
제품 특성 요약
(SPC)
08-08-2022
이 제품에 대한 일부 문서는 현재 사용할 수 없습니다. 고객 서비스에 요청을 보내면 가능한 빨리 알려 드리겠습니다.
요청을 보내십시오.
요청을 보내십시오.
유효 성분:
MELOXICAM
제공처:
DOMINION PHARMACAL
ATC 코드:
M01AC06
INN (국제 이름):
MELOXICAM
복용량:
15MG
약제 형태:
TABLET
구성:
MELOXICAM 15MG
관리 경로:
ORAL
패키지 단위:
100
처방전 유형:
Prescription
치료 영역:
OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS
제품 요약:
Active ingredient group (AIG) number: 0131676004; AHFS:
승인 상태:
APPROVED
승인 날짜:
2003-12-02
제품 특성 요약
PRODUCT MONOGRAPH
PR
DOM-MELOXICAM
Meloxicam Tablets, House standard
7.5 mg and 15 mg
NON-STEROIDAL ANTI-INFLAMMATORY DRUG (NSAID)
DOMINION PHARMACAL
DATE OF REVISION:
6111 Royalmount Ave., Suite # 100
AUG 08, 2022
Montreal, Quebec
H4P 2T4
CONTROL NO: 261586
_DOM-MELOXICAM Product Monograph Page 2 of 47_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
..................................................... 3
SUMMARY PRODUCT INFORMATION
................................................................... 3
INDICATIONS AND CLINICAL
USE.........................................................................
3
CONTRAINDICATIONS
.............................................................................................
4
WARNINGS AND PRECAUTIONS
............................................................................
5
ADVERSE REACTIONS
...........................................................................................
16
DRUG
INTERACTIONS............................................................................................
22
DOSAGE AND
ADMINISTRATION.........................................................................
27
OVERDOSAGE
.........................................................................................................
28
ACTION AND CLINICAL PHARMACOLOGY
........................................................ 29
STORAGE AND
STABILITY....................................................................................
33
DOSAGE FORMS, COMPOSITION AND PACKAGING
.......................................... 33
PART II: SCIENTIFIC
INFORMATION..........................................................................
35
PHARMACEUTICAL
INFORMATION.....................................................................
35
CLINICAL TRIALS
...................................................................................................
36
DETAILED PHARMACOLOGY
...............................................................................
39
TOXICOLOGY
.............................
전체 문서 읽기
